RecruitingNCT05814640
Sequenced medication and CBT options for adolescents with depression
About this title
Read the official source — NCT05814640Medication studyAges 13–18China
Understand this study
Who could participate?
Listed age limits: 13 years to 18 years.
- Listed locations
- ChongqingSee all locations and recruitment
- Study phase
- Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: February 20, 2023
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 520
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Behavioural, Drug
- Study phase
- Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- China
- Age range
- From 13 Years to 18 Years
- Official registry ID
- NCT05814640
- Official title
Show the full official title
Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD): a Pragmatic Clinical Trial
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Chongqing
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is First Affiliated Hospital of Chongqing Medical University, a university.
Does this study involve medication?
Yes. The study involves medication, including Fluoxetine, Sertraline, Vortioxetine, Duloxetine, Aripiprazole, Lithium Carbonate and Olanzapine.
Who can participate?
Listed age limits: 13 years to 18 years.
Is this study still recruiting?
The registry lists this study as recruiting.
